Abstract
The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.
MeSH terms
-
Biomarkers, Tumor / metabolism
-
Copper Radioisotopes / chemistry
-
Copper Radioisotopes / pharmacokinetics
-
Copper Radioisotopes / therapeutic use*
-
Humans
-
Immunoconjugates / therapeutic use
-
Isomerism
-
Mucin-1 / metabolism
-
Radioimmunodetection
-
Radioimmunotherapy
-
Radioisotopes / chemistry
-
Radioisotopes / pharmacokinetics
-
Radioisotopes / therapeutic use*
-
Radiopharmaceuticals / therapeutic use*
-
Rhenium / chemistry
-
Rhenium / pharmacokinetics
-
Rhenium / therapeutic use*
-
Urinary Bladder Neoplasms / diagnosis
-
Urinary Bladder Neoplasms / radiotherapy*
Substances
-
Biomarkers, Tumor
-
Copper Radioisotopes
-
Immunoconjugates
-
Mucin-1
-
Radioisotopes
-
Radiopharmaceuticals
-
Rhenium